Compositions and methods for the treatment of tumor of hematopoietic origin
AssigneeGenentech, Inc.
InventorsWesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Claims92
An isolated monoclonal antibody produced by a hybridoma 7G7.7.8 designated ATCC Accession Number PTA-6336 that binds to a polypeptide having the amino acid sequence of SEQ ID NO:2.
An isolated monoclonal antibody produced by a hybridoma 1F9.1.1 designated ATCC Accession Number PTA-6332 that binds to a polypeptide having the amino acid sequence of SEQ ID NO:4.
An isolated monoclonal antibody produced by a hybridoma 2A10.1.1 designated ATCC Accession Number PTA-6333 that binds to a polypeptide having the amino acid sequence of SEQ ID NO:4.
An isolated monoclonal antibody produced by a hybridoma 7D11.1.1 designated ATCC Accession Number PTA-6340 that binds to a polypeptide having the amino acid sequence of SEQ ID NO:6.
An isolated monoclonal antibody produced by a hybridoma 6F2.1.1 designated ATCC Accession Number PTA-6337 that binds to a polypeptide having the amino acid sequence of SEQ ID NO:8.
An isolated monoclonal antibody produced by a hybridoma 1A3.1.1 designated ATCC Accession Number PTA-6339 that binds to a polypeptide having the amino acid sequence of SEQ ID NO:10.
An isolated antibody comprising a heavy chain which is encoded by the nucleotide sequence of SEQ ID NO:13 and a light chain which is encoded by the nucleotide sequence of SEQ ID NO:14.
Dependencies are inferred from the claim text.